Skip to main content

Table 1 Patient’s neo-epitopes to which T cell reactivity was detected.

From: Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4

Patient % Tumor # Mut # SLP # SSP Genes Mut cDNA Mut a.a. % Mut (WES) Peptide Peptide ID
NIC3 21 21 24 47 PARVA c.328C>G p.P110R 11 NLPLSPIPFELDREDTMLEENEVRT L01
      G3BP1 c.244G>A p.A82T 11 NCHTKIRHVDAHTTLNDGVVVQVMG L13
      G3BP1 c.244G>A p.A82T 11 IRHVDAHTTL S13-1
NIC4 48 30 39 46 ACTR10 c.638G>A p.R213H 15 SVPEGVLEDIKAHTCFVSDLKRGLK L06
      RAE1 c.1106A>G p.X369W 13 WWLETLAQPELFLSTLPHLCTNLGP L20-2
      PDP1 c.1024C>T p.R342W 45 PKSEAKSVVKQDWLLGLLMPFRAFG L29
      PDP1 c.1024C>T p.R342W 45 SEAKSVVKQDW S29-1
      PDP1 c.1024C>T p.R342W 45 SEAKSVVKQDWL S29-2
NIC5 72 49 71 94
NIC6 79 23 24 32
NIC7 78 33 44 70
NIC15 43 15 15 108 QRICH1 c.1054C>A p.V352F 14 VHVSGSPTALAAFKLEDDKEKMVGT L11
NIC17 51 45 47 60
  1. % Tumor tumor purity, Mut mutation, SLP synthetic long peptides, SSP synthetic short peptides, WES reads in whole-exome sequencing.